China Biologic Products, Inc. (NASDAQ:CBPO) – Stock analysts at Jefferies Group dropped their FY2018 earnings estimates for shares of China Biologic Products in a note issued to investors on Thursday. Jefferies Group analyst J. Wong now anticipates that the biopharmaceutical company will post earnings per share of $5.78 for the year, down from their previous forecast of $5.88. Jefferies Group has a “Buy” rating on the stock. Jefferies Group also issued estimates for China Biologic Products’ FY2019 earnings at $6.87 EPS.
CBPO has been the topic of several other research reports. Zacks Investment Research lowered shares of China Biologic Products from a “hold” rating to a “sell” rating in a research report on Friday, May 5th. BidaskClub downgraded China Biologic Products from a “hold” rating to a “sell” rating in a report on Sunday, July 16th. Finally, Goldman Sachs Group, Inc. (The) started coverage on China Biologic Products in a report on Tuesday, May 30th. They set a “neutral” rating on the stock. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $132.00.
China Biologic Products (NASDAQ:CBPO) traded up 0.85% during midday trading on Monday, reaching $94.00. 115,211 shares of the company’s stock traded hands. The stock has a market capitalization of $2.56 billion, a price-to-earnings ratio of 24.47 and a beta of 1.70. China Biologic Products has a 52 week low of $92.23 and a 52 week high of $133.19. The company’s 50-day moving average price is $104.90 and its 200 day moving average price is $107.96.
China Biologic Products (NASDAQ:CBPO) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.05. China Biologic Products had a net margin of 31.55% and a return on equity of 21.86%. The company had revenue of $89.28 million during the quarter, compared to the consensus estimate of $97.33 million. During the same period in the previous year, the firm earned $1.26 earnings per share. China Biologic Products’s revenue for the quarter was down 2.3% on a year-over-year basis.
A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its position in China Biologic Products by 694.1% in the first quarter. BlackRock Inc. now owns 1,508,096 shares of the biopharmaceutical company’s stock worth $151,007,000 after buying an additional 1,318,183 shares during the last quarter. UBS Asset Management Americas Inc. boosted its position in China Biologic Products by 9.3% in the first quarter. UBS Asset Management Americas Inc. now owns 198,220 shares of the biopharmaceutical company’s stock worth $19,848,000 after buying an additional 16,933 shares during the last quarter. Bank of America Corp DE boosted its position in China Biologic Products by 67.3% in the first quarter. Bank of America Corp DE now owns 56,118 shares of the biopharmaceutical company’s stock worth $5,619,000 after buying an additional 22,583 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in China Biologic Products by 9.5% in the first quarter. Goldman Sachs Group Inc. now owns 58,559 shares of the biopharmaceutical company’s stock worth $5,863,000 after buying an additional 5,091 shares during the last quarter. Finally, Vontobel Asset Management Inc. bought a new position in China Biologic Products during the first quarter worth $5,735,000. Institutional investors own 74.09% of the company’s stock.
About China Biologic Products
China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment.
What are top analysts saying about China Biologic Products Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for China Biologic Products Inc. and related companies.